Literature DB >> 23573910

Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum-based chemotherapy.

Jianli Chen, Matthew Hurford, Sabeen Mekan, Henry Simpkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23573910      PMCID： PMC3683085          DOI： 10.1111/bjh.12324

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.

Authors:  Markus Raderer; Stefan Wöhrer; Rupert Bartsch; Gerald Prager; Johannes Drach; Michael Hejna; Alexander Gaiger; Karl Turetschek; Ulrich Jaeger; Berthold Streubel; Christoph C Zielinski
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

2.  An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.

Authors:  I Chau; A Webb; D Cunningham; M Hill; S Rao; S Ageli; A Norman; K Gill; A Howard; D Catovsky
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

3.  Proapoptotic activity of new glutathione S-transferase inhibitors.

Authors:  Paola Turella; Claudia Cerella; Giuseppe Filomeni; Angela Bullo; Francesca De Maria; Lina Ghibelli; Maria Rosa Ciriolo; Maurizio Cianfriglia; Maurizio Mattei; Giorgio Federici; Giorgio Ricci; Anna Maria Caccuri
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

4.  The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.

Authors:  Harsh Vardhan Jain; Michael Meyer-Hermann
Journal:  Cancer Res       Date:  2010-12-17       Impact factor: 12.701

5.  Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.

Authors:  Yasuhiro Oki; Peter McLaughlin; Barbara Pro; Fredrick B Hagemeister; Archie Bleyer; Evelyn Loyer; Anas Younes
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

6.  Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survival.

Authors:  Catherine Thieblemont; Delphine Rolland; Lucile Baseggio; Pascale Felman; Sophie Gazzo; Evelyne Callet-Bauchu; Alexandra Traverse-Glehen; Rémi Houlgatte; Kai Fu; Dennis Weisenburger; Daphne De Jong; Elaine S Jaffe; Andreas Rosenwald; German Ott; Bertrand Coiffier; Françoise Berger
Journal:  Leuk Lymphoma       Date:  2008-07

Review 7.  The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors:  Danyelle M Townsend; Kenneth D Tew
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

8.  Prognostic value of GST-pi expression in diffuse large B-cell lymphomas.

Authors:  V Ribrag; S Koscielny; I Carpiuc; C Cebotaru; H Vande Walle; M Talbot; P Fenaux; J Bosq
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

9.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

10.  GST-pi and P-170 co-expression in multiple myeloma.

Authors:  M Petrini; D Di Simone; A Favati; L Mattii; P Valentini; B Grassi
Journal:  Br J Haematol       Date:  1995-06       Impact factor: 6.998
  10 in total
  2 in total

1.  Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.

Authors:  Hajime Asada; Hirotaka Tomiyasu; Yuko Goto-Koshino; Yasuhito Fujino; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2015-02-21       Impact factor: 1.267

2.  Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

Authors:  L Sawers; M J Ferguson; B R Ihrig; H C Young; P Chakravarty; C R Wolf; G Smith
Journal:  Br J Cancer       Date:  2014-07-10       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.